Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ASIC3 | Q9UHC3 | 2/20 | 0.55 |
| ▸ | PLAU | P00749 | 1/20 | 0.54 |
| ▸ | DRD2 | P14416 | 2/20 | 0.51 |
| ▸ | DRD3 | P35462 | 2/20 | 0.51 |
| ▸ | PNMT | P11086 | 5/20 | 0.48 |
| ▸ | CD44 | P16070 | 1/20 | 0.48 |
| ▸ | MAOB | P27338 | 1/20 | 0.48 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.46 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.46 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15331352 | 0.82 | ASIC3 (0.51) | ASIC3PLAUDRD2DRD3PNMT | |
| SCHEMBL29867656 | 0.81 | ASIC3 (0.55) | ASIC3PLAUDRD2DRD3PNMT | |
| SCHEMBL120623 | 0.81 | ASIC3 (0.55) | ASIC3PLAUDRD2DRD3PNMT | |
| SCHEMBL5811572 | 0.81 | ASIC3 (0.55) | ASIC3PLAUDRD2DRD3PNMT | |
| SCHEMBL22542122 | 0.81 | ASIC3 (0.55) | ASIC3PLAUDRD2DRD3PNMT | |
| SCHEMBL31083766 | 0.81 | ASIC3 (0.55) | ASIC3PLAUDRD2DRD3PNMT | |
| SCHEMBL1696305 | 0.81 | ASIC3 (0.55) | ASIC3PLAUDRD2DRD3PNMT | |
| Hydrochloric Acid SCHEMBL3118464 | 0.81 | ASIC3 (0.50) | ASIC3PLAUDRD2DRD3PNMT | |
| Hydrochloric Acid SCHEMBL29954861 | 0.81 | ASIC3 (0.50) | ASIC3PLAUDRD2DRD3PNMT | |
| SCHEMBL27725285 | 0.81 | ASIC3 (0.50) | ASIC3PLAUDRD2DRD3PNMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7144894-B2 | Sulfonamide bicyclic compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-12-05 | — | — | US | disclosed |
| WO-2006034480-A2 | SULFONAMIDE BICYCLIC COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-03-30 | — | — | WO | disclosed |
| US-20060063799-A1 | Sulfonamide bicyclic compounds | BRISTOL-MYERS SQUIBB COMPANY | 2006-03-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060063799-A1 | Sulfonamide bicyclic compounds | APP, BACE1, IAPP | ASIC3 639/4885PLAU 2530/4885DRD2 4467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.